Welcome to our dedicated page for Senseonics Holdings SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Senseonics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Senseonics Holdings's regulatory disclosures and financial reporting.
Senseonics Holdings, Inc. (SENS) director Douglas A. Roeder reported an open-market purchase of 13,953.2843 shares of common stock on 2026-08-19 at a weighted average price of $8.98 per share, in multiple trades between $8.95 and $8.99. Following this transaction, he directly holds 171,191.2843 shares.
Sessa Capital IM, L.P., as investment manager to certain funds, and John Petry report beneficial ownership of Senseonics Holdings, Inc. common stock. They report beneficial ownership of 12,437,532 shares of common stock, including 8,000,000 shares issuable upon exercise of pre-funded warrants held by the Sessa funds. Their reported stake represents 9.9% of the outstanding common stock, based on 52,864,750 shares outstanding as of June 30, 2026. The warrants are subject to a 9.9% “Blocker” that prevents exercises which would cause the reporting persons’ beneficial ownership to exceed 9.9%.
Senseonics Holdings, Inc. reported sharply higher revenue but larger losses for the six months ended June 30, 2026. Total revenue was $26,194 thousand, more than doubling from $12,906 thousand a year earlier, driven mainly by U.S. commercialization of the Eversense E3 and Eversense 365 CGM systems and the transition of European distribution back in-house.
Operating expenses increased substantially as the company built its direct sales, marketing, and support infrastructure and continued product development, resulting in an operating loss of $67,834 thousand and a net loss of $69,038 thousand, or $1.33 basic and diluted net loss per share.
Liquidity improved through equity and debt financing. As of June 30, 2026, the company held $142.7 million in unrestricted cash, cash equivalents and marketable securities. It raised approximately $86.0 million in net proceeds from a May 2026 equity and pre-funded warrant offering, received about $6.2 million via an at-the-market program, and expanded its Hercules senior secured term loan facility to up to $140.0 million, with $55.0 million drawn. Net cash used in operating activities was $62,163 thousand, and management states that available resources and expected cash flows are sufficient for at least the next twelve months.
Senseonics Holdings, Inc. reported record results for the quarter ended June 30, 2026, with total revenue of $14.5 million, an increase of approximately 120% from $6.6 million a year earlier. U.S. revenue rose to $12.6 million, while revenue outside the U.S. was $1.9 million, reflecting the integration of European commercial operations and growth in the Eon Care program.
Gross profit was $8.6 million, for gross margin of approximately 59%, up from 47% in the prior-year quarter. Higher investment in the Gemini and Freedom development programs and commercial integration drove research and development expenses to $11.6 million and selling, general and administrative expenses to $32.9 million, resulting in a net loss of $36.7 million, or $0.63 per share. As of June 30, 2026, cash, restricted cash and cash equivalents totaled $143.0 million and outstanding indebtedness was $55.5 million. Senseonics raised its full-year 2026 revenue guidance to $62–$66 million and gross margin guidance to 58%–61%, citing commercial momentum and the global roll-out of Eversense 365.
BlackRock, Inc. has reported a passive ownership stake in SENSEONICS HOLDINGS, INC. common stock on Schedule 13G. As of June 30, 2026, BlackRock and certain of its business units beneficially owned 2,764,170 shares of SENSEONICS common stock, representing 6.6% of the outstanding class. BlackRock reports sole voting powersole dispositive power
Prince Douglas S reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Douglas S. Prince received a grant of 1,515 shares of common stock. This stock was issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees. The grant value equaled $8,120.40, based on a $5.36 closing share price. Following this award, Prince directly holds 69,331 shares of Senseonics common stock.
ROEDER DOUGLAS A reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Douglas A. Roeder received a stock award of 2,751 common shares as compensation. The grant was made in lieu of quarterly cash retainer fees and was valued at $14,745.36, based on a $5.36 closing share price on July 1, 2026.
After this non‑market grant, Roeder directly holds 157,238 shares of Senseonics common stock, reflecting routine director compensation rather than an open-market purchase or sale.
Fiorentino Edward reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Edward Fiorentino received a grant of common stock as part of his non-employee director compensation. He was issued 2,635 shares of common stock in lieu of quarterly cash retainer fees, based on a value of $14,123.60 at a price of $5.36 per share, which was the closing price on July 1, 2026. Following this award, he directly owns 85,974 shares of Senseonics common stock.
Senseonics Holdings director Steven Edelman received a stock grant as part of his board compensation. He acquired 2,402 shares of common stock on July 1, 2026 at a reference price of $5.36 per share, issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees.
The grant value was $12,874.72, based on the Nasdaq Global Select Market closing price on that date. Following this award, Edelman directly holds 91,083 shares of Senseonics common stock, reflecting routine equity-based director compensation rather than an open-market purchase.
Senseonics Holdings, Inc. Chief Medical Officer Francine Kaufman reported a routine share disposition related to taxes. On the vesting of restricted stock units, 4,010 shares of common stock were withheld at a reference value of $7.18 per share to satisfy withholding tax obligations. After this tax-withholding event, Kaufman directly holds 177,057 shares of Senseonics common stock. This transaction does not represent an open-market purchase or sale, but an automatic mechanism to cover taxes tied to equity compensation.